66FF1C46-83F0-4EEC-9871-448C8C7EA3AE
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.005256241787121
- age_years
- 62
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.610
- E2F_TARGETS+0.605
- G2M_CHECKPOINT+0.578
- MYC_TARGETS_V2+0.566
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.532
- UNFOLDED_PROTEIN_RESPONSE+0.505
- MTORC1_SIGNALING+0.504
- IL6_JAK_STAT3_SIGNALING+0.495
- TGF_BETA_SIGNALING+0.489
- TNFA_SIGNALING_VIA_NFKB+0.485
Top 10 suppressed
- KRAS_SIGNALING_DN-0.415
- PANCREAS_BETA_CELLS-0.212
- SPERMATOGENESIS-0.144
- MYOGENESIS-0.101
- BILE_ACID_METABOLISM-0.017
- HEDGEHOG_SIGNALING+0.027
- APICAL_SURFACE+0.036
- XENOBIOTIC_METABOLISM+0.077
- HEME_METABOLISM+0.114
- ESTROGEN_RESPONSE_EARLY+0.115
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.983 |
| 2 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.980 |
| 3 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.979 |
| 4 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.978 |
| 5 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.978 |
| 6 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.977 |
| 7 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.975 |
| 8 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.975 |
| 9 | SRR934730 | — | — | 0.972 |
| 10 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.971 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.605 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.578 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.566 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.532 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.505 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.504 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.495 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.489 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.485 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.484 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.476 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.474 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.465 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.449 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.443 | Idelalisib | — uncovered |
| APOPTOSIS | 0.429 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.429 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.405 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.398 | Inavolisib | — uncovered |